Clinical Trials Logo

Restenosis, Coronary clinical trials

View clinical trials related to Restenosis, Coronary.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04968977 Completed - Clinical trials for Left Main Coronary Artery Disease

PCI vs. CABG in UPLM-ISR

LM-DRAGON
Start date: January 1, 2001
Phase:
Study type: Observational [Patient Registry]

Left main (LM) coronary artery disease is associated with high morbidity and mortality owing to the large myocardial territory at risk for ischemia. Evidence from randomized controlled trials supports that percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for LM disease is an acceptable treatment strategy compared with coronary artery bypass graft surgery in patients with low or intermediate anatomic complexity. However in-stent restenosis (ISR) after DES in LM disease is still occurring with an incidence of 9,7%. Studies comparing the percutaneous coronary intervention with coronary artery bypass grafting (CABG) in the treatment of in-stent restenosis in unprotected left main have been scarce. While surgical revascularization is considered to be the standard treatment for this kind of stent failure, owing to a high risk of perioperative morbidity and mortality, the restoration of flow with PCI may be a reliable alternative. Additionally, it is not clear whether re-PCI is safe in these patients. Therefore, the purpose of the present study was to compare long-term outcomes following PCI or CABG for UPLM-ISR disease.